EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey

Cecilia Lacey, Khaya Clark, James Riley Debacker, Hunter Stuehm iD, Michelle Hungerford, Trisha Milnes, Kirsten Johansson, Rosemarie Mannino, Julie N Graff, Dawn Konrad-Martin

Cancer Medicine · 2026

DOI: 10.1002/cam4.71566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Cecilia Lacey und 9 weiteren Autor:innen. Beteiligte Einrichtung: VA Pittsburgh Geriatric Research, Education, and Clinical Center, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Ototoxicity, Neoplasms, Antineoplastic Agents. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Department of Veterans Affairs, RRD VA, NIDCD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Identify factors influencing audiological care for chemotherapy‐induced ototoxicity from the perspectives of oncology providers in the Veterans Health Administration (VA), and quantify audiology service use among Veterans receiving ototoxic chemotherapies.

Methods

We surveyed VA oncology providers to identify barriers and facilitators to ototoxicity management (OtoM). We also conducted a VA‐wide retrospective cohort analysis over a 5‐year period to quantify audiology service use among Veterans who received cisplatin, carboplatin, or oxaliplatin chemotherapy.

Results

A total of 30,643 Veterans received platinum‐based chemotherapy from 2014 to 2019. Few of them (< 10% on cisplatin, < 5% on carboplatin or oxaliplatin) accessed audiology services within a year of treatment. Of the 8702 patients on cisplatin, only 9.6% had two or more audiology encounters. Thirty‐six oncology providers completed our survey. Most providers believed OtoM should be routine for patients on cisplatin (97%) or carboplatin (70%), but they overestimated audiology service provision levels relative to our analysis. Most providers would consider giving a different chemotherapy drug (73%) or decrease the dose (56%) for patients with ototoxicity, yet only 36% routinely referred patients to audiology. Access, perceived need, and resources were major barriers to OtoM, while care coordination was a primary facilitator.

Conclusions

OtoM is a care‐gap for Veterans with cancer, despite its perceived value to VA oncology providers. Cisplatin and carboplatin frequently add hearing loss and tinnitus to survivors' treatment burdens. This study offers insights into oncology providers' views on OtoM, guiding efforts to address the identified care gap.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OtotoxicityNeoplasmsAntineoplastic AgentsHumansRetrospective StudiesVeteransUnited StatesCarboplatinMaleFemaleAudiologyCisplatinMiddle AgedSurveys and QuestionnairesOxaliplatinUnited States Department of Veterans AffairsHearing Loss

Stichwörter der Autor:innen

Otology/Neurotologyaudiologychemotherapydrug‐related side effects and adverse reactionsototoxicityprofessional practice gapssensorineural hearing loss

Substanzen

CarboplatinCisplatinAntineoplastic AgentsOxaliplatin

Autor:innen und Institutionen

  • VA Pittsburgh Geriatric Research, Education, and Clinical Center, Pittsburgh, Pennsylvania, USA.
  • VA Rehabilitation Research, Development & Translation Services Center, National Center for Rehabilitative Auditory Research, VA Portland Healthcare System, Portland, Oregon, USA.
  • Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA.
  • VA Health Services Research & Development Center of Innovation, Center to Improve Veteran Involvement in Care, VA Portland Healthcare System, Portland, Oregon, USA.
  • Department of Otolaryngology/Head & Neck Surgery, Oregon Health & Science University, Portland, Oregon, USA.
  • Department of Audiology and Speech Pathology, VA Augusta Healthcare System, Augusta, Georgia, USA.

ORCID-Profile: Hunter Stuehm

Förderung

  • U.S. Department of Veterans Affairs
  • RRD VA
  • NIDCD NIH HHS
  • National Institute on Deafness and Other Communication Disorders

Zitieren

APA

Lacey, C., Clark, K., Debacker, J. R., Stuehm, H., Hungerford, M., Milnes, T., Johansson, K., Mannino, R., Graff, J. N., & Konrad-Martin, D. (2026). Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey. Cancer Medicine. https://doi.org/10.1002/cam4.71566

Vancouver

Lacey C, Clark K, Debacker JR, Stuehm H, Hungerford M, Milnes T, et al. Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey. Cancer Medicine. 2026. doi:10.1002/cam4.71566

BibTeX
@article{Lacey2026,
  author = {Lacey, Cecilia and Clark, Khaya and Debacker, James Riley and Stuehm, Hunter and Hungerford, Michelle and Milnes, Trisha and Johansson, Kirsten and Mannino, Rosemarie and Graff, Julie N and Konrad-Martin, Dawn},
  title = {Identifying Gaps and Opportunities to Improve Ototoxicity Management in Veterans With Cancer: Evidence From a Retrospective Cohort and Oncology Provider Survey},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.71566}
}
Kostenlos starten →